The use of statins: A case of misleading priorities?: National guidance that does not link costs and benefits is worthless

BMJ

Volumn 315, Issue 7112, 1997, Pages 826-828

  Freemantle, Nick ^a   Barbour, Ruth ^b   Johnson, Richard ^b   Marchment, Mike ^b   Kennedy, Andrew ^c  

^a UNIVERSITY OF YORK   (United Kingdom)

^b Warwickshire Health Authority   (United Kingdom)

^c Croft Medical Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN; SIMVASTATIN; STATIN;

BUDGET; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG USE; EDITORIAL; HEALTH CARE PLANNING; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL;

ADULT; AGED; ANTILIPEMIC AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; MIDDLE AGED; PRACTICE GUIDELINES;

EID: 0030922773     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.315.7112.826     Document Type: Editorial

References (12)

1. Standing Medical Advisory Committee. The use of statins. London: Department of Health, 1997 (11061 HCD Aug 97(04)).
2. Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN. Targeting lipid lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet 1996; 348: 387–388.
3. Calman K. CMO's Update 15. A communication to all doctors from the Chief Medical Officer. London; Department of Health, 1997.
4. Winyard G. SMAC statement on use of statins. London: Department of Health, 1997 (EL(97)41 11060 HCD 750 1P Aug 97).
5. Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.
6. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009.
7. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–1307.
8. Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995; 346: 1467–1471.
9. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Part II: analysis and examples. Br J Cancer 1977; 35: 1–39.
10. Faculty of Public Health Medicine. Lipid lowering-how to draw the line. Guidance for directors of public health on drawing up local guidelines for cholesterol testing. London: Royal College of Physicians, 1997.
11. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302.
12. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE extension (AIREX) study. Acute infarction ramipril efficacy. Lancet 1997; 349: 1493–1497.